Skip to content

Emotion and Symptom-Focused Engagement (EASE) for Caregivers

Emotion and Symptom-Focused Engagement (EASE) for Caregivers: A Phase III Randomized Controlled Trial of an Intervention Targeting Traumatic Stress in Parents of Children With Cancer

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06367556
Acronym
EASE
Enrollment
306
Registered
2024-04-16
Start date
2025-02-14
Completion date
2028-10-01
Last updated
2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caregiver Burden, Pediatric Cancer, Trauma and Stressor Related Disorders

Brief summary

The goal of this Phase III randomized controlled trial is to evaluate the effectiveness of a novel psychotherapeutic intervention called Emotion and Symptom-focused Engagement (EASE) in parents caring for a child or adolescent with cancer. The main question it aims to answer is: \- Is EASE plus usual care associated with less severe traumatic stress symptoms over six months, measured by area under the curve, when compared to usual care alone in the parents of children diagnosed with cancer in the preceding six months? For the primary outcome analysis, area under the curve will be calculated for each participant. The statistical significance of the difference between arms will also be evaluated. Participants in both groups will complete questionnaires package at enrolment, and 4, 8, and 12 weeks, and 6 months after enrolment. They will also be invited to participate in optional qualitative interviews to better understand their experience.

Interventions

BEHAVIORALEmotion and Symptom-Focused Engagement (EASE)

EASE sessions are directed to provide relational support, affect regulation, and problem-solving related to cancer in the child, to changes in spousal, family, and other relationships, and to the burden of multiple individual and family responsibilities.

Sponsors

The Hospital for Sick Children
CollaboratorOTHER
Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Masking description

Quantitative outcome assessors and data analysts will be blinded to participant treatment group. Blinding is not possible for trial participants, intervention providers, or pediatric oncology teams, as assignment cannot be hidden from these individuals.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Self-identified primary family caregiver/guardian (i.e., parent assuming the majority of care activities) of a child: i) \<18yo; ii) diagnosed with a new or relapsed life-threatening cancer within the preceding six months (disease-type eligibility per the Pediatric Oncology Group of Ontario Networked Information System); and iii) receiving active cancer therapy; * Age ≥18 years; and, * Able to complete outcome measures and engage in EASE in English, which need not be their first language.

Exclusion criteria

* Impairment in cognitive functioning or communication that would preclude participation in EASE sessions or outcome measure completion, as determined by the research team; * Receiving formal ongoing psychotherapy at the time of recruitment; * Active suicidal intention, based on an item in the Distress Assessment and Response Tool (DART) that has been widely used in suicidal intention screening in cancer; or, * Child not expected to survive past the duration of trial, as determined by the child's medical team.

Design outcomes

Primary

MeasureTime frameDescription
The Stanford Acute Stress Reaction Questionnaire [SASRQ]6-monthsSASRQ is a 30-item self-report measure with a rating scale of 0-30 (total range 0-150) that assesses the presence and severity of traumatic stress symptoms. Higher scores reflect greater severity.

Secondary

MeasureTime frameDescription
The SF-36v2 Health Survey6-monthsSF-36v2 consists of eight scales yielding two summary measures: physical and mental health. It can be scored using both norm-based scoring (NBS) algorithms and the original 0-100 scoring system, where higher scores indicate better health status.
Caregiver Self-Efficacy in Contributing to Patient Self Care Scale [CSE-CSC]6-monthsCSE-CSC is a 10-item scale (standardized score 0-100) of to measure the extent of self-efficacy of the caregiver when contributing to patient self-care in the complex care context. Higher scores indicate higher self-efficacy.
Family Adaptability and Cohesion Evaluation Scales III [FACES-III]6-monthsFACES-III is a 20-item measure with a rating scale of 1-5 that will be used to assess parent perceived family functioning. 10-items measure family cohesion and 10-items measure adaptability (range 10-50, respectively), with higher scores for each domain indicating greater connectivity or flexibility compared to disengagement or rigidity.
Clinical Evaluation Questionnaire [CEQ]6-monthsCEQ is a 7-item patient-reported experience measure with a rating scale of 0-4 that will assess the perceived benefits that caregivers experience in their interactions with healthcare providers in domains relevant to advanced cancer. A total score is calculated by summing the item scores where higher scores reflect greater perceived benefit.
Family Satisfaction with End-of-Life Care Tool, 10-item version [FAMCARE-10]6-monthsFAMCARE-10 was developed to measure family caregiver satisfaction with the care of patients with advanced cancer with a rating scale of 0 (dissatisfied) to 2 (satisfied) where higher total scores reflect greater satisfaction.
Patient Health Questionnaire [PHQ-9]6-monthsPHQ-9 is a 9-item measure with a rating scale of 0-3 (total range 0-27) that assesses the presence and severity of depressive symptoms. Higher scores reflect greater depression severity.
The PTSD Checklist for DSM-5 [PCL-5]6-monthsPCL-5 is a 20-item self-report measure with a rating scale of 0-4 (total range 0-80) that assesses the presence and severity of traumatic stress symptoms. Higher scores reflect greater severity.

Other

MeasureTime frameDescription
Experiences in Close Relationships Scale [ECR-16]6-monthsECR-16 will be used to measure attachment security with a rating scale of 1 (disagree) to 7 (agree) with two subscales: Attachment Anxiety and Attachment Avoidance. Both subscales have a total score of 56 where higher scores indicate high attachment insecurity.
Hope of Improvement subscale of the Therapy Expectation and Evaluation Scale [PATHEVH]BaselineThis 4-item subscale (items 1, 4, 5, and 9) will be used to assess expectation of the effectiveness of Emotion and Symptom-focused Engagement (EASE) in the treatment arm. They are rated from 1 (absolutely wrong) to 5 (absolutely right) and items 1, 5, and 9 are reversed-scored prior to summing all items (total score range 4-20) with higher scores reflecting more positive outcome expectation.
Caregiver Reaction Assessment Scale [CRA]6-monthsCRA is a 24-item scale that measures the impact of providing care at the subscale level, with no overall summative score. Items have a rating scale of 1 (strongly disagree) to 5 (strongly agree) with five subscales that assess impact on schedule (/25), impact on finances (/15), lack of family support (/25), impact on health (/20), and self-esteem (/30).The items in four of the scales (all except self-esteem) are generally phrased in a negative connotation such that higher scores indicate a more negative experience for that subscale.
ENRICHD Social Support Instrument [ESSI]6-monthsESSI is a 7-item scale used to measure perceived social support. The first six items have a rating scale of 1 (none of the time) to 5 (all of the time) and the seventh is scored 4 for 'yes' and 2 for 'no'. Total scores range from 8 to 34. A lower total score reflects less support.

Countries

Canada

Contacts

Primary ContactDr. Lindsay Jibb, RN, PhD
lindsay.jibb@sickkids.ca416-813-7654
Backup ContactElham Hashemi, MA
elham.hashemi@sickkids.ca416-813-7654

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026